Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2026-05-25 @ 12:29 PM
Study NCT ID:
NCT00220402
Status:
COMPLETED
Last Update Posted:
2008-11-24
First Post:
2005-08-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SP738
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None